GlassScriptPhysician profile
Thomas A Russo
NPI 1902804412
$3,477.41
in general payments reported to CMS, 2019-2025
20 companies · $964 in 2025
The $964 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $265 · 2023: $668 · 2024: $1,580 · 2025: $964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,212.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,417.88 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $707.87 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $282.18 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $265.21 | 2024-2025 | |
| Glaxosmithkline, LLC. | $199.85 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $143.33 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $87.83 | 2023-2024 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $47.03 | 2024 | Gemtesa |
| Amgen INC. | $46.73 | 2023-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.18 | 2023 | Jardiance |
| Abbott Laboratories | $43.06 | 2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $38.33 | 2025 | Auvelity |
| Lilly USA, LLC | $28.30 | 2024 | Zepbound, Mounjaro |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.24 | 2025 | Rejoyn |
| Beta Bionics, INC. | $19.64 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $19.50 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.10 | 2022 | |
| Dexcom, INC. | $16.88 | 2024 | Dexcom G6 Transmitter |
| Tactile Systems Technology INC | $15.27 | 2024 | Flexitouch Plus, Entre Plus |
| Vertex Pharmaceuticals Incorporated | $14.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Russo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.